
ODTX
Healthcare · Biotechnology · $920.0M market cap
$19.14-0.96 (-4.8%)Nov 13, 4:26 PM EST
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · -2.3% over 90 days · 30-day revisions 0 up, 1 down
Beat estimates in 1 of the last 3 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 4, 2026 | Before the open | -1.13 | -1.10 | +2.7% |
| Aug 5, 2026 | Time not confirmed | -0.83 | -1.26 | -51.8% |
| Jun 3, 2026 | Time not confirmed | -1.28 | -6.75 | -427.0% |
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic…